678PD - Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

L Rimassa,R.K Kelley,T Meyer,B.-Y Ryoo,P Merle,J.-W Park,J.-F Blanc,H.Y Lim,A Tran,A.E Borgman-Hagey,D.O Clary,E Wang,A.-L Cheng,A.B El-Khoueiry,G.K Abou-Alfa

doi:10.1093/annonc/mdz247.006

678PD - Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

L Rimassa, R.K Kelley + Show 13 more

Open Access

https://doi.org/10.1093/annonc/mdz247.006

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 13	License type: publisher-specific-oa

Affiliation: University of Ulsan, Samsung Medical Center, National Taiwan University Hospital

#Research Grant #Low Biomarker Levels + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

678PD - Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

Full Text